Insider Transactions in Q2 2021 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,812
-0.96%
|
$217,984
$32.38 P/Share
|
|
Jun 28
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,812
+0.95%
|
$163,488
$24.15 P/Share
|
|
Jun 25
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
83,372
-9.9%
|
$2,667,904
$32.02 P/Share
|
|
Jun 25
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.89%
|
$950,000
$19.47 P/Share
|
|
Jun 17
2021
|
Daniel K Spiegelman Director |
SELL
Open market or private sale
|
Direct |
3,139
-11.95%
|
$94,170
$30.52 P/Share
|
|
Jun 03
2021
|
Heinrich Dreismann Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+13.33%
|
-
|
|
Jun 03
2021
|
Dennis Langer Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+12.55%
|
-
|
|
Jun 03
2021
|
Lee Nisley Newcomer Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+24.12%
|
-
|
|
Jun 03
2021
|
Daniel K Spiegelman Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+32.85%
|
-
|
|
Jun 03
2021
|
Rashmi Kumar Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+25.89%
|
-
|
|
Jun 03
2021
|
S. Louise Phanstiel Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+13.91%
|
-
|
|
Jun 03
2021
|
Colleen F Reitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+24.12%
|
-
|
|
Jun 03
2021
|
Daniel Skovronsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,848
+25.32%
|
-
|
|
May 28
2021
|
Kevin Richard Haas Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
344
+0.61%
|
$5,160
$15.86 P/Share
|
|
May 28
2021
|
Jayne B. Hart Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,082
+1.31%
|
$16,230
$15.86 P/Share
|
|
May 28
2021
|
Daniel K Spiegelman Director |
SELL
Open market or private sale
|
Direct |
7,142
-34.73%
|
$199,976
$28.99 P/Share
|
|
May 27
2021
|
Daniel K Spiegelman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,889
-43.59%
|
-
|
|
May 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
19,360
-6.79%
|
$600,160
$31.97 P/Share
|
|
May 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,360
+6.36%
|
$367,840
$19.47 P/Share
|
|
Apr 27
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
40,000
-13.08%
|
$1,240,000
$31.47 P/Share
|
|
Apr 27
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+11.56%
|
$760,000
$19.47 P/Share
|
|
Apr 19
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,649
-2.46%
|
$179,523
$27.01 P/Share
|
|
Apr 01
2021
|
Eric Santa Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,420
+50.0%
|
-
|